TeamBest™ Global Celebrates 16 Years of Cyclotron Innovation and Its Role in the Future of Theranostics




TeamBest™ Global Celebrates 16 Years of Cyclotron Innovation and Its Role in the Future of Theranostics

WASHINGTON–(BUSINESS WIRE)–Cyclotrons have fundamentally transformed nuclear medicine and cancer therapy over the past decade, with major milestones driven by Best ABT, Best Cyclotron Systems (BCS) and TeamBest Global (TBG), under the leadership of Krishnan Suthanthiran. Their innovations have enabled more advanced diagnostic imaging, targeted therapies, and global expansion of life-saving technologies.​

BCS set out to design and build high-performance cyclotrons, establishing expertise in cyclotrons ranging from 1 MeV to 70 MeV and beyond. Its vision was to advance global healthcare by delivering compact, efficient, and versatile cyclotrons capable of producing a variety of vital radioisotopes for diagnostic and therapeutic purposes.

In March 2015, BCS achieved a milestone with the commissioning of the B70 cyclotron at INFN Legnaro, Italy. This 70 MeV compact cyclotron, designed for radioisotope production and research, earned recognition among international cyclotron and radiopharmaceutical experts for its performance and reliability. Building on this success, Best ABT developed the BG-95 and B-11 cyclotrons, optimized for on-site production of PET tracers, including F-18, N-13, C-11, and Ga-68—crucial for imaging in cardiology, oncology, and neurology. Their compact, shielded designs allow seamless installation adjacent to clinical imaging suites, thereby improving workflow and expanding patient access to cutting-edge diagnostics.​

TBG’s technology portfolio spans 6 MeV research cyclotrons to high-energy 70 MeV multiparticle systems, leading to over 15 new cyclotron orders in the U.S. alone and expanding facilities across North America, Europe, and India. Innovations like alpha cyclotrons enable the production of isotopes such as Actinium-225 and have the potential to revolutionize theranostics—the combined use of therapy and diagnostics for oncology. These advancements further strengthen TeamBest’s leadership in cancer diagnosis and treatment technologies.

TBG’s cyclotrons are designed for high-yield, safe production of essential radioisotopes, including Technetium-99m, which is fundamental to nuclear imaging, and newer isotopes that support targeted cancer therapies.

Every week, Best ABT/Best Cyclotron delivers thousands of radiopharmaceutical doses worldwide, helping clinicians detect diseases at their earliest stages. TBG’s commitment to ongoing innovation has shaped the nuclear medicine field. By leading advances in cyclotron design, including the move toward alpha- and deuteron-particle capabilities, TeamBest reaffirms its commitment to global health and technological excellence, celebrating nearly two decades of impact and paving the way for future breakthroughs.

For more information, visit www.bestcyclotron.com.

Contacts

Krishnan Suthanthiran, Global Cell/WhatsApp +1 571-437-9802, krish@teambest.com

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients




Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

LYON, France–(BUSINESS WIRE)–#Biotechnology–Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study.

The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-1010¹ in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS² colorectal cancer (CRC).

Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date.

“We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminary clinical signals are very promising and support further evaluation of subsequent cohorts – we are observing trends in efficacy that are stronger than anything that has been previously reported in hard-to-treat solid tumors.”

The trial is continuing to enroll patients at higher dose levels, and additional data on exploratory analyses (cytokine profiles, immunophenotyping, PBMC markers, ctDNA, HLA expression, tumor necrosis, immune infiltration, and TLS evolution) and efficacy will be communicated as the trial progresses.

Brenus’ next report is expected to be released in Q1 2026, as a key milestone in advancing STC-1010 for patients with advanced MSS “cold” colorectal cancer.

About Brenus Pharma
Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response against evolving tumor cells in solid tumors.

www.brenus-pharma.com

About SGC Platform
SGC platform is a next-generation in vivo immunotherapy platform based on Stimulated Ghost Cells (SGC), generated by controlled physical or chemical stress and hapten-induced immune flare, to target and destroy tumor cells while anticipating their evolution.

Contacts

contact@brenus-pharma.com

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement




Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

EMERYVILLE, Calif.–(BUSINESS WIRE)–Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock.

The combined offering price for each share of common stock and accompanying warrant was $1.58 (or $1.57999 with respect to each pre-funded warrant and accompanying warrant). The pre-funded warrants have an exercise price of $0.00001 per share, are exercisable immediately upon issuance, and will not expire until fully exercised. The common warrants have an exercise price of $1.39 per share, are exercisable upon issuance and will expire on the fifth anniversary of the initial exercise date.

The transactions closed on January 6, 2026, with approximately $8.0 million aggregate gross proceeds. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.

“The successful closing of this financing underscores the continued investor support for our clinical vision and provides Estrella with additional resources to pursue our clinical objectives,” said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. “We are well-positioned to advance our lead program, EB103, through its Phase II trial and towards key value-inflection points. We believe this is a critical step in developing our ARTEMIS® T-cell therapies for patients who are not eligible for currently marketed therapies.”

Aegis Capital Corp. acted as exclusive placement agent for the offerings. Winston & Strawn LLP acted as counsel to the Company. Sichenzia Ross Ference Carmel LLP acted as counsel to Aegis Capital Corp.

The securities described above (excluding the Common Warrants and the shares of common stock underlying the Common Warrants) were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283770), declared effective by the U.S. Securities and Exchange Commission (“SEC”) on December 19, 2024. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement.. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

The offer and sale of the Common Warrants in the concurrent private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the Common Warrants and underlying shares of common stock may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the Common Warrants.

Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Estrella Immunopharma, Inc.

Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contacts

Investor Relations

Estrella Immunopharma, Inc.

IR@estrellabio.com

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA




ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status

High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact

Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026

SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne—BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA^® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA^® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST.

HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also showed a statistically significant and clinically meaningful improvement in overall survival (OS) (mOS: 26.4 months, HR=0.72 [95% CI: 0.57, 0.90]; P=0.0043), resulting in a 28% reduction in the risk of death and a greater than 7-month improvement in mOS. These PFS and OS benefits were observed in the ZIIHERA plus TEVIMBRA and chemotherapy arm versus the control arm regardless of PD-L1 expression level, with approximately one-third of enrolled patients with tumors classified as PD-L1 < 1%. ZIIHERA plus chemotherapy showed a clinically meaningful survival benefit with a mOS of 24.4 months, a strong trend toward statistical significance at the time of this first interim analysis for OS.

“The HERIZON-GEA-01 results are encouraging, with median overall survival for tislelizumab plus zanidatamab and chemotherapy surpassing two years, an outcome that marks a significant advancement in the treatment of metastatic HER2+ gastroesophageal adenocarcinoma,” said Manish Shah, M.D., Chief of the Solid Tumor Service and Director of Gastrointestinal Oncology at Weill Cornell Medicine and a medical oncologist at NewYork-Presbyterian/Weill Cornell Medical Center, who serves as a paid advisory board member for Jazz Pharmaceuticals, Inc. and BeOne Medicines Ltd. “Unlike prior studies in HER2+ GEA with checkpoint blockade therapy, the addition of tislelizumab demonstrated meaningful activity even in TAP PD-L1 < 1%, suggesting a potential new treatment option for this subgroup, while broadening choices for patients with PD-L1 ≥1%.”

Further highlights from the HERIZON-GEA-01 results include:

• TEVIMBRA added to ZIIHERA and chemotherapy (n=302; mPFS: 12.4 months, HR=0.63 [95% CI: 0.51, 0.78], P=<0.0001) resulted in a 37% reduction in the risk of disease progression and a greater than 4-month improvement in mPFS.
• Patients receiving ZIIHERA plus chemotherapy (n=304; mPFS: 12.4 months, HR=0.65 [95% CI: 0.52, 0.81], P=<0.0001) showed a 35% reduction in the risk of disease progression and a similar greater than 4-month improvement in mPFS.
• These results compare favorably to mPFS of 8.1 months in patients treated with trastuzumab plus chemotherapy.
• In the PD-L1 negative subgroup (TAP score <1%), the HR results for PFS were 0.47 [95% CI: 0.32, 0.69] in the ZIIHERA plus TEVIMBRA and chemotherapy arm and the HR results for OS were 0.49 [95% CI: 0.33, 0.73].
• In the PD-L1 positive subgroup (TAP score >1%), the HR results for PFS were 0.65 [95% CI: 0.49, 0.86] in the ZIIHERA plus TEVIMBRA and chemotherapy arm and the HR results for OS were 0.82 [95% CI: 0.60, 1.10].
• Both experimental arms demonstrated improvements in the key secondary endpoints of objective response rate (ORR) and duration of response (DOR) versus the control arm, with ZIIHERA and chemotherapy resulting in an ORR of 69.6% with a median DOR of 14.32 months (CI 95%: 11.53, 21.85). The ZIIHERA plus TEVIMBRA and chemotherapy arm induced an ORR of 70.7%, with the median DOR reaching 20.70 months (CI 95%: 12.55, 37.65), highlighting TEVIMBRA’s essential role in the durability of response observed with the regimen.

“The comprehensive results of the HERIZON-GEA-01 study, particularly the improvement in overall survival shown in the TEVIMBRA plus ZIIHERA and chemotherapy arm, pave the way for the adoption of a new standard in first-line HER2-positive metastatic GEA,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. “BeOne holds commercial rights for ZIIHERA in most of Asia Pacific, where the GEA burden is highest. With these data, we anticipate the opportunity to expand access so more patients can benefit.”

The safety profile of ZIIHERA in combination with chemotherapy, with or without TEVIMBRA, was consistent with the known effects of HER2-directed therapy and immunotherapy, and no new safety signals were identified. Duration of treatment was longest on the ZIIHERA plus TEVIMBRA and chemotherapy arm. Rates of Grade ≥3 treatment-related adverse events (TRAEs) were 71.8% with ZIIHERA plus TEVIMBRA and chemotherapy, 59.0% with ZIIHERA plus chemotherapy, and 59.6% with trastuzumab plus chemotherapy. Rates of discontinuation of ZIIHERA or trastuzumab due to TRAEs were 11.9% with ZIIHERA plus TEVIMBRA and chemotherapy, 8.5% with ZIIHERA plus chemotherapy, and 2.3% in the trastuzumab plus chemotherapy arm. The most common Grade ≥3 treatment-related adverse event (TRAE) was diarrhea (24.5% of patients with ZIIHERA plus TEVIMBRA and chemotherapy; 20.0% with ZIIHERA plus chemotherapy; and 12.9% of patients in the trastuzumab plus chemotherapy arm). Importantly, discontinuation of either ZIIHERA or trastuzumab due to treatment-related diarrhea was uncommon (4.1% of patients with ZIIHERA plus TEVIMBRA and chemotherapy, 1.3% with ZIIHERA plus chemotherapy, and 0% of patients in the trastuzumab plus chemotherapy arm). Treatment-emergent diarrhea generally occurred early in treatment and resolved within 3 weeks. The manageable safety profile supports the feasibility of these combinations in the first-line metastatic setting.

These results will be submitted for publication in a peer-reviewed journal. BeOne intends to submit supplemental Biologics License Applications to the U.S. FDA for TEVIMBRA and to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for TEVIMBRA and ZIIHERA, based on these data. The company also intends to work with authorities in its licensed territories to expedite regulatory submissions in these markets.

About the HERIZON-GEA-01 Phase 3 Trial

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with Jazz Pharmaceuticals, to evaluate and compare the efficacy and safety of ZIIHERA plus chemotherapy, with or without TEVIMBRA, to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries. Appropriate patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: ZIIHERA in combination with chemotherapy and TEVIMBRA; ZIIHERA in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial is evaluating dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

About Gastroesophageal Adenocarcinoma

Gastroesophageal adenocarcinoma (GEA), which includes cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide. Approximately 20% of GEA patients have HER2-positive disease^1,2,3, which has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 30% for gastric cancer and about 19% for GEA.⁴

About ZIIHERA (zanidatamab)

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.⁵

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA also has been approved in both the U.S. and the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

ZIIHERA is a registered trademark of Zymeworks BC Inc.

About TEVIMBRA (tislelizumab)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 35 countries and regions across 70 trials, including 22 registration-enabling studies. TEVIMBRA is approved in at least one indication in 48 markets, and more than 1.8 million patients have been treated globally.

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

The information in this press release is intended for a global audience. Product indications vary by region.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of ZIIHERA and TEVIMBRA; the potential of TEVIMBRA plus ZIIHERA and chemotherapy to become a new standard in first-line HER2-positive metastatic GEA; the potential opportunity to expand access; BeOne’s plans to expand TEVIMBRA’s label; BeOne’s expectations regarding ZIIHERA’s and TEVIMBRA’s clinical development and regulatory milestones; BeOne’s plans to submit the data for publication; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne Medicines.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

¹ Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.

² Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.

³ Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.

⁴ Battaglin F, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International. 2018;18(99).

⁵ ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

Contacts

Investor Contact
Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact
Kyle Blankenship

+1 667-351-5176

media@beonemed.com

Statistical Process Control (SPC) and Control Charts for Laboratory Compliance Course (ONLINE EVENT: Jan 27, 2026) – ResearchAndMarkets.com




Statistical Process Control (SPC) and Control Charts for Laboratory Compliance Course (ONLINE EVENT: Jan 27, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Statistical Process Control (SPC) and Control Charts for Laboratory Compliance (Jan 27, 2026)” training has been added to ResearchAndMarkets.com’s offering.

Compliance under GLP can be difficult. The setting up of a system to monitor the performance of methods and instruments can lessen this. Statistical Process Control (SPC) uses control charts and statistical guidelines to monitor a wide variety of things in the compliant laboratory. These generate a proactive system to assess problems early on and quickly to be handled by adjustments rather than the strict situation of a non-compliance event.

Control charts are based on the distribution of data expected in a laboratory, the Gaussian distribution of occurrences. There are well-defined probabilities for the data. Guidelines for good or unacceptable behavior are well known. The most common of these are Nelson Rules, in use for over a century. With a wide selection of variables to monitor, assessing performance can be simple.

Who Should Attend:

• Lab Chemists
• Lab Managers
• Lab Technicians
• Lab Analysts
• Industries into Compliance Methodology (Biotech, Pharma)
• Quality Personnel
• Manufacturing Personnel
• Operations/Production Managers
• Production Supervisors
• Supplier Quality personnel
• Quality Engineering
• Quality Assurance Managers, Engineers
• Process or Manufacturing Engineers or Managers

Key Topics Covered:

• Control charts and their underlying statistics
• Choosing variables to monitor
• Maintaining the records
• Planning adjustments
• Examples and walk through of control chart implementation and use
• Review of the relevant statistics

Speaker

Dr. John C. Fetzer has been doing liquid chromatographic method development for over 35 years. His PhD was in studies of various types of chromatography. He has authored or co-authored over 50 papers on LC separations, has served on the advisory boards of the Journal of Chromatography, Analytical Chemistry, and Analytical and Bioanalytical Chemistry. He supervised the Good Laboratory Practices accreditation of a large research chromatography laboratory and has taught numerous short courses on GLP and ISO 17025 compliance.

For more information about this training visit https://www.researchandmarkets.com/r/a9of1q

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Nanobubbles Market Research Report 2026-2036 with Detailed Profiles of Over 55 Nanobubble Equipment Manufacturers Worldwide – ResearchAndMarkets.com




Nanobubbles Market Research Report 2026-2036 with Detailed Profiles of Over 55 Nanobubble Equipment Manufacturers Worldwide – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Global Nanobubbles Market 2026-2036” report has been added to ResearchAndMarkets.com’s offering.

The Global Nanobubbles Market Report 2026-2036 provides detailed analysis, revenue forecasts, and strategic insights into the rapidly evolving nanobubble industry from 2026 through 2036. This report delivers actionable intelligence for investors, manufacturers, end users, and stakeholders seeking to understand market dynamics, identify growth opportunities, and navigate the competitive landscape of the global nanobubbles industry.

Nanobubbles, also known as ultrafine bubbles, represent an emerging technology with applications spanning multiple industries. These microscopic gas-filled cavities, typically less than 200 nanometers in diameter, exhibit unique properties that distinguish them from conventional bubbles, including exceptional stability, high surface area-to-volume ratios, and the ability to remain suspended in liquids for extended periods due to Brownian motion.

The global nanobubble market is experiencing significant growth. Agriculture represents one of the largest application areas for nanobubble technology. Farmers and agricultural operations utilize nanobubble-infused water to improve crop yields, enhance root oxygenation, and reduce the need for chemical inputs. Various generation techniques and administration methods have been developed specifically for agricultural deployment.

Aquaculture has emerged as another significant market segment. Fish farms and shellfish operations employ nanobubbles to increase dissolved oxygen levels in water, improving fish health, growth rates, and survival. The technology addresses critical challenges in intensive aquaculture operations where oxygen depletion poses constant risks.

Biomedical and biopharma applications represent a high-value market segment. Nanobubbles show promise in drug delivery systems, diagnostic imaging, and therapeutic applications. Their biocompatibility and ability to carry therapeutic gases make them attractive for medical research and clinical applications. Food and Beverage Production leverages nanobubbles for cleaning, sanitation, and preservation purposes. The technology helps extend shelf life, reduce microbial contamination, and improve processing efficiency without relying heavily on chemical additives.

Environmental Remediation utilizes nanobubbles for treating contaminated water and soil. The technology accelerates the breakdown of pollutants and supports bioremediation processes, addressing growing environmental concerns and regulatory requirements. Water Purification represents a substantial market opportunity, with nanobubbles enhancing treatment processes in both municipal and industrial settings. The technology improves oxidation, flotation, and disinfection processes while potentially reducing chemical usage.

Surface Cleaning and Disinfection applications benefit from nanobubbles’ ability to penetrate microscopic crevices and lift contaminants from surfaces. This capability proves valuable in industrial cleaning, semiconductor manufacturing, and healthcare settings. Additional markets include Oil and Gas operations, where nanobubbles assist in enhanced oil recovery and produced water treatment; Coolants and Cooling Towers, where they improve heat transfer efficiency; and Steel Production, where they contribute to processing improvements.

The nanobubble equipment manufacturing sector has grown considerably, with over 55 companies now operating globally. These manufacturers range from established industrial equipment providers to specialized startups focused exclusively on nanobubble technology. While the technology shows considerable promise, limitations exist across different market segments. Factors potentially hindering market penetration include equipment costs, the need for further validation studies, and varying levels of awareness among potential end users. However, growing environmental concerns, water scarcity issues, and the push for sustainable industrial practices continue driving interest in nanobubble solutions.

The nanobubble market stands at an inflection point, transitioning from an emerging technology to mainstream industrial adoption across multiple sectors, with substantial growth anticipated through 2036.

Report Contents Include:

• Detailed definition and classification of nanobubbles, including surface nanobubbles and bulk nanobubbles
• Comprehensive analysis of nanobubble properties, generation techniques, and preparation methods
• Technology limitations assessment segmented by market application
• Comparative analysis of nanobubbles versus related materials and competing technologies
• Total addressable market size evaluation with market penetration likelihood assessment
• Global market revenue forecasts from 2021-2036 with both conservative and high-growth estimates
• Market segmentation by end-use application and geographic region
• In-depth analysis of ten key end-use markets including market drivers, overview, applications, outlook, and SWOT analysis
• Detailed profiles of over 55 nanobubble equipment manufacturers worldwide
• Assessment of generation techniques and administration methods by industry sector
• End-Use Markets:
  • Agriculture and crop production
  • Aquaculture and fish farming
  • Biomedical and biopharmaceutical applications
  • Food and beverage production
  • Oil and gas industry
  • Environmental remediation
  • Surface cleaning and disinfection
  • Water and wastewater purification
  • Coolants and cooling tower systems
  • Steel production
• Geographic Markets Covered:
  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Each market segment includes comprehensive analysis of key drivers, current market overview, motivations for adoption, specific applications, future outlook projections, and detailed SWOT analysis examining strengths, weaknesses, opportunities, and threats facing nanobubble technology deployment.

This essential market intelligence report equips decision-makers with the comprehensive data and strategic insights necessary to capitalize on emerging opportunities within the dynamic global nanobubbles market.

Companies Featured

• Acniti LLC
• Agrona B.V.
• Anzai Kantetsu Co. Ltd. MCS
• AquaB Nanobubble Innovations Ltd.
• Aquamar B.V.
• AquaPro Solutions Pte Ltd.
• Asuplus Nanobubble Technology
• Aura Tec Co. Ltd.
• Biokavitus srl
• BioNano International Ltd.
• ChucaoTech
• Custom Fluids Pty Ltd
• Earthwise Global
• En Solucion
• EnH Co. Ltd.
• Enviro-Vision
• EOD Europe
• Exomira Medicine Inc.
• Fawoo Nanotech Co. Ltd.
• Fine Bubble Technologies Pty Ltd.
• Geon Intertec Co. Ltd.
• GreenTech California
• HACK UFB Co. Ltd.
• Hinode Sangyo Co. Ltd.
• Honour Tech
• Huw Nanotech
• Jiil Co. Ltd
• Kairospace Technologies
• Kran Nanobubble
• Ligaric Co. Ltd.
• Living Energies & Co.
• Moleaer Inc.
• NAC Co. Ltd.
• Nakashima
• Nangatech Sp. z o.o.

For more information about this report visit https://www.researchandmarkets.com/r/xlns66

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

The AIgency™ is a Best Place to Work: MERGE Recognized by Built In for Blending AI Innovation with Employee Wellness




The AIgency™ is a Best Place to Work: MERGE Recognized by Built In for Blending AI Innovation with Employee Wellness

Top honors in Atlanta and Colorado highlight a forward-thinking culture that empowers the “whole person” with pioneering technology and inclusivity.

CHICAGO–(BUSINESS WIRE)–MERGE, a marketing and technology agency, celebrates its recognition as one of the Best Places to Work in 2026 by Built In. The annual awards honor employers across the U.S. whose benefits and compensation set the standard for today’s workforce.

For the fourth consecutive year, MERGE has been recognized by Built In for its outstanding workplace culture. Securing the titles of Best Midsize Places to Work in Colorado and Best Places to Work in Atlanta this year reflects MERGE’s nationwide commitment to championing a culturally rich and supportive environment across all eight of its offices including Boston, Chicago, Kansas City, Los Angeles, New York, and Raleigh.

Built In uses a data-driven approach that evaluates companies on the totality of their offerings, including compensation, benefits, and company-wide culture programs. This year’s distinction underscores MERGE’s philosophy of empowering the “whole person.” The agency believes when employees feel deeply supported, professionally connected, and genuinely healthy, exceptional work follows.

“This honor reflects our philosophy: to maximize the impact that people have, you have to invest in the best for people,” said Erica Denner, Chief People Officer at MERGE. “This recognition from Built In validates our commitment to a ‘whole person’ culture. We strive to create an environment where mental, physical, and professional well-being are inextricably linked.”

MERGE continues to evolve the agency model into the AIgency, blending human creativity with data and technology. This forward-thinking approach extends to its employee experience. The agency recently earned a perfect score on the Human Rights Campaign’s 2025 Corporate Equality Index, highlighting its dedication to inclusivity. Employees engage through nine Employee Resource Groups and a thriving mentorship program that connects colleagues across departments and locations. Furthermore, MERGE invests in physical and mental well-being through its Benefits Built Different program that includes Oura Ring and Function Health, alongside a Lifestyle Spending Account for personal wellness activities. For MERGE, a superior employee experience is the foundation of client excellence. Being named 2025 Agency of the Year in the Modern Healthcare and Ad Age Healthcare Marketing Impact Awards validates this approach, proving that a culture rooted in inclusivity and innovation yields exceptional results.

“As we transition into a true AIgency, we are looking at how technology can serve our internal community just as effectively as it serves our clients,” added Erica. “Innovation at MERGE isn’t limited to our output; it’s embedded in our employee experience. By combining advanced wellness tech and data-driven benefits with a deeply human culture of mentorship and inclusivity, we are building a workplace that isn’t just ready for the future—it’s actively defining it.”

Now in its eighth year, Built In’s Best Places to Work program celebrates the companies shaping the future of work. In a rapidly evolving AI-first job market, recognition as a Best Place to Work helps employers stand out as trusted brands when candidates turn to tools like ChatGPT and Google AI Overviews to research where to work next.

“Today’s candidates discover the companies they want to work for using AI tools,” said Maria Christopoulos Katris, Founder & CEO of Built In. “Earning a Best Place to Work award not only signals to candidates that you invest in your people, it’s a lever to strengthen how AI search tools understand and represent your company’s story.”

To learn more about the 2026 Best Places to Work program and view all winners, visit https://employers.builtin.com/best-places-to-work/.

About MERGE

MERGE, the 2025 Agency of the Year winner in the Modern Healthcare and Ad Age Healthcare Marketing Impact Awards, is a marketing and technology agency built for the intersection of health and wellness. We combine deep expertise in health and consumer behavior with strategy, creativity, experience technology, and digital marketing to design personalized experiences that drive meaningful results.

Powered by human insight, creativity, and AI, we weave storytelling through technology to turn complexity into clarity — strengthening relationships between people and brands.

With 750+ specialists across Atlanta, Boston, Chicago, Denver, Kansas City, Los Angeles, New York, and Raleigh, MERGE partners with leading brands like Abbott, GE Healthcare, American Express, T-Mobile, and Coach to advance health, wellness, and happiness.

Contacts

Mary Joseph | mjoseph@mergeworld.com

Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer




Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer

Dr. Skerlj brings significant drug development experience to lead biotech startup in its mission to develop next-gen autoimmune treatments

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rhapsogen, an immunology company redefining the treatment paradigm for autoimmune diseases, today announced the appointment of Renato Skerlj, Ph.D., as the company’s new Chief Executive Officer, effective immediately.

Rhapsogen was launched by Catalio Capital Management’s venture strategy earlier this year. The company was co-founded by Prof. Jeffrey Ravetch, M.D., Ph.D., of Rockefeller University, and Prof. Eric Sundberg, Ph.D. of Emory University, both of whom are leaders in the immunology field and have made fundamental contributions to the understanding of how the immune system interacts directly with antibodies to protect against infection or cause autoimmune disease. In addition to his primary appointment, Dr. Jeffery Ravetch is a Catalio Venture Partner.

Dr. Skerlj is a seasoned biotechnology executive with more than 30 years of experience in drug discovery and development. He has authored over 70 scientific publications, is an inventor on more than 60 patents, and has played key leadership roles in advancing multiple therapeutics from discovery through clinical development and regulatory approval. Most recently, Dr. Skerlj served as President and Chief Executive Officer of Expansion Therapeutics, where he led the advancement of a proprietary RNA-targeting platform and overseeing company growth and financing. Previously, he was Co-Founder and Chief Scientific Officer of X4 Pharmaceuticals and a co-inventor of mavorixafor, which received FDA approval in 2024 for the treatment of WHIM syndrome. Across his career, Dr. Skerlj has built and led high-performing R&D organizations, contributed to successful financings and strategic transactions, and helped translate scientific innovation into impactful medicines.

“I am very excited by what we are building at Rhapsogen and look forward to working with our world-class team of immunology experts to deliver the solutions that autoimmune patients need and deserve,” said Dr. Skerlj.

“Dr. Skerlj’s leadership experience coupled with his deep drug development expertise make him well suited to maximize the potential of Rhapsogen’s first-in-class approach in autoimmune disease. We are thrilled to continue supporting the company’s growth under Dr. Skerlj’s leadership,” said Matthew Hobson, Ph.D., Principal at Catalio Capital Management, who will be also joining Rhapsogen’s Board of Directors.

About Rhapsogen

Rhapsogen is a Cambridge, MA-based immunology company focused on redefining the autoimmune treatment paradigm by developing next generation therapies that rapidly neutralize pathogenic autoantibodies and prevent autoimmune inflammation and tissue damage while preserving the immune system’s ability to fight infection. The company was founded in 2025 by Dr. Jeffrey Ravetch (Rockefeller University) and Dr. Eric Sundberg (Emory University).

To learn more, please visit www.rhapsogen.com.

About Catalio Capital Management, LP:

Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.

Contacts

Media
catalio@rubenstein.com